Noxopharm Completes Final Single-Dose Group in Autoimmune Diseases Drug Candidate Trial, Shares Fall 6%

MT Newswires Live

2025/09/08

Noxopharm (ASX:NOX) said the fourth and last single-dose group of SOF-SKN, a drug candidate for autoimmune diseases like cutaneous lupus erythematosus, was completed in the HERACLES trial, according to a Monday Australian bourse filing.

The safety steering committee determined the dose level to be safe and tolerable, with no clinically relevant issues identified.

The study aims to evaluate the safety and tolerability profile of SOF-SKN by testing it at four different concentrations. Each group is scheduled to take around two weeks due to several tests, including electrocardiograms, physical exams, participant questionnaires, and numerous blood tests.

The firm's shares fell 6% in recent trading on Monday.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2565757029"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2565757029\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2565757029?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-08 13:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2565757029","market":"fut","top_or_hot":-1,"title":"Noxopharm Completes Final Single-Dose Group in Autoimmune Diseases Drug Candidate Trial, Shares Fall 6%","media":"MT Newswires Live","content":"<html><body><p> Noxopharm (ASX:NOX) said the fourth and last single-dose group of SOF-SKN, a drug candidate for autoimmune diseases like cutaneous lupus erythematosus, was completed in the HERACLES trial, according to a Monday Australian bourse filing.</p><p>The safety steering committee determined the dose level to be safe and tolerable, with no clinically relevant issues identified.</p><p>The study aims to evaluate the safety and tolerability profile of SOF-SKN by testing it at four different concentrations. Each group is scheduled to take around two weeks due to several tests, including electrocardiograms, physical exams, participant questionnaires, and numerous blood tests.</p><p>The firm's shares fell 6% in recent trading on Monday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Noxopharm Completes Final Single-Dose Group in Autoimmune Diseases Drug Candidate Trial, Shares Fall 6%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNoxopharm Completes Final Single-Dose Group in Autoimmune Diseases Drug Candidate Trial, Shares Fall 6%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-08 13:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Noxopharm (ASX:NOX) said the fourth and last single-dose group of SOF-SKN, a drug candidate for autoimmune diseases like cutaneous lupus erythematosus, was completed in the HERACLES trial, according to a Monday Australian bourse filing.</p><p>The safety steering committee determined the dose level to be safe and tolerable, with no clinically relevant issues identified.</p><p>The study aims to evaluate the safety and tolerability profile of SOF-SKN by testing it at four different concentrations. Each group is scheduled to take around two weeks due to several tests, including electrocardiograms, physical exams, participant questionnaires, and numerous blood tests.</p><p>The firm's shares fell 6% in recent trading on Monday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7508","symbol_name":"医药生物股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2565757029","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2565757029","pubTimestamp":1757310418,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Noxopharm  said the fourth and last single-dose group of SOF-SKN, a drug candidate for autoimmune diseases like cutaneous lupus erythematosus, was completed in the HERACLES trial, according to a Monday Australian bourse filing.The safety steering committee determined the dose level to be safe and tolerable, with no clinically relevant issues identified.The study aims to evaluate the safety and tolerability profile of SOF-SKN by testing it at four different concentrations. Each group is scheduled to take around two weeks due to several tests, including electrocardiograms, physical exams, participant questionnaires, and numerous blood tests.The firm's shares fell 6% in recent trading on Monday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7508":"医药生物股","BK7067":"生物科技","NOX.AU":"NOXOPHARM LTD","BK7501":"新冠治疗股"},"translate_title":"Noxopharm完成自身免疫性疾病候选药物试验的最后一个单剂量组，股价下跌6%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NOX.AU":0.9},"content_text":"Noxopharm (ASX:NOX) said the fourth and last single-dose group of SOF-SKN, a drug candidate for autoimmune diseases like cutaneous lupus erythematosus, was completed in the HERACLES trial, according to a Monday Australian bourse filing.The safety steering committee determined the dose level to be safe and tolerable, with no clinically relevant issues identified.The study aims to evaluate the safety and tolerability profile of SOF-SKN by testing it at four different concentrations. Each group is scheduled to take around two weeks due to several tests, including electrocardiograms, physical exams, participant questionnaires, and numerous blood tests.The firm's shares fell 6% in recent trading on Monday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}